Pine Bark Extract for Melasma

Pine bark extract, tested as the French maritime pine product Pycnogenol, has two clinical studies in melasma. The better one randomised 44 women to 75 mg twice a day or placebo for 60 days, on top of a nightly triple combination cream and a tinted SPF 50 sunscreen. Melasma severity (mMASI) fell by 49% with the extract and 34% with placebo, a difference that was statistically significant [1].

The other study gave 30 women 75 mg a day for 30 days with no comparison group; patches shrank and faded, but without a control group you can't tell how much was the extract [2]. A 2026 systematic review of natural products for melasma counted pycnogenol among the agents that lowered severity scores, while warning that small samples and short follow-up limit the evidence [3]. On this base, pine bark extract is at most a possible add-on, not a substitute for the treatments dermatologists rely on.

Melasma is a chronic, relapsing build-up of pigment in facial skin [3], made by pigment cells called melanocytes. In cultured human melanocytes exposed to ultraviolet, infrared and visible light, pine bark extract reduced melanin production and lowered endothelin-1, a signal that stimulates pigment cells; in a separate enzyme assay it cut the activity of tyrosinase (the enzyme that makes melanin) by about 66.5% [4].

People have shown related effects. In a 12-week crossover trial in 76 outdoor workers in Beijing, 100 mg a day of Pycnogenol prevented the skin darkening seen during the dry autumn season, which placebo did not [5]. In 112 women with sun-damaged skin, a different pine bark extract (Flavangenol) lightened age spots over 12 weeks, though the abstract describes no placebo group [6].

The pigment and enzyme results come from cell and enzyme assays [4], and the skin studies were in healthy volunteers or age spots, not melasma [5][6]. Age spots and seasonal tanning are not melasma, so lighter skin in those settings may not carry over. A plausible route to lighter skin makes the trial result more believable; it doesn't show the extract treats melasma on its own.

The randomised trial used 75 mg of Pycnogenol twice a day (150 mg/day) for 60 days, always together with a tinted SPF 50 sunscreen by day and a triple combination cream at bedtime [1]. The uncontrolled study used one 25 mg tablet three times a day with meals (75 mg/day) for 30 days [2].

Both used Pycnogenol, a standardised extract; other pine bark products are not necessarily equivalent. No study has tested how long any lightening lasts after stopping, and melasma tends to relapse [1].

Lima and colleagues randomised 44 women with facial melasma (average age 39, 91% skin phototypes III-IV) to 75 mg Pycnogenol or placebo twice a day for 60 days. Everyone also used a tinted SPF 50 sunscreen and a triple combination cream, and all completed the trial [1].

Both groups improved. mMASI fell by 49% (95% CI 36-61%) with the extract and 34% (16-47%) with placebo, and the reductions in mMASI and in measured colour contrast were greater with the extract (P < 0.05). On a global aesthetic scale, 86% improved with the extract versus 55% with placebo [1]. Quality of life improved in both groups; the abstract does not report a difference between them on that measure.

In 2002, 30 women took 75 mg a day for 30 days. Average melasma area shrank by 25.86 mm² and pigment intensity fell by 0.47 units (both p < 0.001), and 80% were rated as responding. Blood and urine tests stayed normal and no side effects were seen [2]. With no control group, no blinding and only a month of treatment, the result can't separate the extract from seasonal change, sun avoidance or regression to the mean.

A 2026 systematic review of 10 natural-product trials included pycnogenol among agents that cut melasma scores by 20-70%, but judged the overall evidence limited [3]. An evidence-based review of 113 melasma trials ranks triple combination cream and hydroquinone as the most effective, best-studied treatments and names oral tranexamic acid as the promising oral option [7]; a meta-analysis of 22 tranexamic acid trials found oral use gave the largest drop in MASI [9]. Cochrane's review of pine bark extract across chronic disorders included no melasma trials and could draw no firm conclusions on efficacy or safety for any condition [10].

Missing: a trial of pine bark extract on its own against placebo, any trial longer than 60 days, any follow-up after stopping, and replication by a second group. The add-on design also means the benefit was measured on top of strong treatment, so it may not hold for someone using sunscreen alone. For another oral antioxidant with a melasma pair page here, see glutathione for melasma.

Tolerability was good in both melasma studies: the randomised trial found no adverse effects related to the oral treatment [1], and the uncontrolled study saw no side effects and normal blood and urine tests after 30 days [2]. Memorial Sloan Kettering's professional monograph lists irritability and lower energy as possible reactions and hypersensitivity to pine bark as a contraindication [8].

Studies lasted 60 days at most, and Cochrane found safety reporting across pine bark trials too poor for firm conclusions [10]. Neither melasma study reports on pregnant or breastfeeding women, so safety there is unknown.

The documented interaction is with anticoagulant and antiplatelet drugs, because pine bark can inhibit platelet aggregation [8]. In the melasma trial the extract was taken alongside triple combination cream and sunscreen without problems [1]. No study has looked at combining it with oral tranexamic acid, a prescription melasma treatment.